Urology-Related Conditions Should Not Be Overlooked in Women with Polycystic Ovary Syndrome.
作者信息
Al-Shaiji Tariq Faisal
机构信息
Urology Unit, Department of Surgery, Jaber Al-Ahmad Al-Jaber Al-Sabah Hospital, Kuwait City, Kuwait.
出版信息
Rev Bras Ginecol Obstet. 2021 Oct;43(10):793. doi: 10.1055/s-0041-1736552. Epub 2021 Nov 16.
Abstract
摘要
相似文献
1
Urology-Related Conditions Should Not Be Overlooked in Women with Polycystic Ovary Syndrome.
Rev Bras Ginecol Obstet. 2021 Oct;43(10):793. doi: 10.1055/s-0041-1736552. Epub 2021 Nov 16.
2
Sexual function in infertile women with polycystic ovary syndrome and unexplained infertility.
Am J Obstet Gynecol. 2017 Aug;217(2):191.e1-191.e19. doi: 10.1016/j.ajog.2017.04.034. Epub 2017 Apr 26.
3
Ghrelin is independently associated with anti-mullerian hormone levels in obese but not non-obese women with polycystic ovary syndrome.
Endocrine. 2017 Mar;55(3):907-913. doi: 10.1007/s12020-016-1210-4. Epub 2016 Dec 21.
4
Increased anti-Mullerian hormone levels and ovarian size in a subgroup of women with functional hypothalamic amenorrhea: further identification of the link between polycystic ovary syndrome and functional hypothalamic amenorrhea.
Am J Obstet Gynecol. 2016 Jun;214(6):714.e1-6. doi: 10.1016/j.ajog.2015.12.055. Epub 2016 Jan 6.
5
Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study.
Am J Obstet Gynecol. 1996 Apr;174(4):1224-9; discussion 1229-32. doi: 10.1016/s0002-9378(96)70665-8.
6
[Obesity and hormone function changes in female patients with polycystic ovaries].
Med Pregl. 2003 Sep-Oct;56(9-10):476-80. doi: 10.2298/mpns0310476r.
7
Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome.
J Clin Endocrinol Metab. 1989 Jun;68(6):1027-32. doi: 10.1210/jcem-68-6-1027.
8
Relationship of the metabolic syndrome and obesity to polycystic ovary syndrome: a controlled, population-based study.
Am J Obstet Gynecol. 2001 Feb;184(3):289-96. doi: 10.1067/mob.2001.109596.
9
Tackling polycystic ovary syndrome.
Drug Ther Bull. 2001 Jan;39(1):1-5. doi: 10.1136/dtb.2001.3911-a.
10
Hyperandrogenemia in polycystic ovary syndrome: exploration of the role of free testosterone and androstenedione in metabolic phenotype.
PLoS One. 2014 Oct 13;9(10):e108263. doi: 10.1371/journal.pone.0108263. eCollection 2014.
本文引用的文献
1
Polycystic Ovary Syndrome (PCOS) Transition at Menopause.
J Midlife Health. 2021 Jan-Mar;12(1):30-32. doi: 10.4103/jmh.jmh_37_21. Epub 2021 Apr 17.
2
Fowler's syndrome--progesterone deficiency or oestrogen excess?
Nat Rev Urol. 2014 Oct;11(10):553. doi: 10.1038/nrurol.2013.277-c1. Epub 2014 Aug 26.
3
Is polycystic ovarian syndrome a risk factor for urolithiasis?
Urolithiasis. 2013 Aug;41(4):361-2. doi: 10.1007/s00240-013-0564-9. Epub 2013 Apr 21.
4
The cause and natural history of isolated urinary retention in young women.
J Urol. 2002 Jan;167(1):151-6.
5
Abnormal electromyographic activity of the urethral sphincter, voiding dysfunction, and polycystic ovaries: a new syndrome?
BMJ. 1988 Dec 3;297(6661):1436-8. doi: 10.1136/bmj.297.6661.1436.
Zotero 插件